Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis.

Peterfy C, DiCarlo J, Emery P, Genovese MC, Keystone EC, Taylor PC, Schlichting DE, Beattie SD, Luchi M, Macias W.

J Rheumatol. 2019 Jan 15. pii: jrheum.171469. doi: 10.3899/jrheum.171469. [Epub ahead of print]

2.

Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis.

Keystone EC, Genovese MC, Schlichting DE, de la Torre I, Beattie SD, Rooney TP, Taylor PC.

J Rheumatol. 2018 Jan;45(1):14-21. doi: 10.3899/jrheum.161161. Epub 2017 Aug 15.

3.

Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis.

Kremer JM, Genovese MC, Keystone E, Taylor PC, Zuckerman SH, Ruotolo G, Schlichting DE, Crotzer VL, Nantz E, Beattie SD, Macias WL.

Arthritis Rheumatol. 2017 May;69(5):943-952. doi: 10.1002/art.40036.

4.

Towards High Capacity Li-ion Batteries Based on Silicon-Graphene Composite Anodes and Sub-micron V-doped LiFePO4 Cathodes.

Loveridge MJ, Lain MJ, Johnson ID, Roberts A, Beattie SD, Dashwood R, Darr JA, Bhagat R.

Sci Rep. 2016 Nov 29;6:37787. doi: 10.1038/srep37787.

5.

Baricitinib in Patients with Refractory Rheumatoid Arthritis.

Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, Beattie SD, Koch AE, Cardillo TE, Rooney TP, Macias WL, de Bono S, Schlichting DE, Smolen JS.

N Engl J Med. 2016 Mar 31;374(13):1243-52. doi: 10.1056/NEJMoa1507247.

6.

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate.

Keystone EC, Taylor PC, Drescher E, Schlichting DE, Beattie SD, Berclaz PY, Lee CH, Fidelus-Gort RK, Luchi ME, Rooney TP, Macias WL, Genovese MC.

Ann Rheum Dis. 2015 Feb;74(2):333-40. doi: 10.1136/annrheumdis-2014-206478. Epub 2014 Nov 27.

7.

Ti-doped LiAlH4 for hydrogen storage: synthesis, catalyst loading and cycling performance.

Liu X, Langmi HW, Beattie SD, Azenwi FF, McGrady GS, Jensen CM.

J Am Chem Soc. 2011 Oct 5;133(39):15593-7. doi: 10.1021/ja204976z. Epub 2011 Sep 8.

PMID:
21863886
8.

Temporal and spatial imaging of hydrogen storage materials: watching solvent and hydrogen desorption from aluminium hydride by transmission electron microscopy.

Beattie SD, Humphries T, Weaver L, McGrady GS.

Chem Commun (Camb). 2008 Oct 7;(37):4448-50. doi: 10.1039/b807091a. Epub 2008 Jul 28.

PMID:
18802586
9.

Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia.

Milicevic Z, Raz I, Beattie SD, Campaigne BN, Sarwat S, Gromniak E, Kowalska I, Galic E, Tan M, Hanefeld M.

Diabetes Care. 2008 Feb;31 Suppl 2:S155-60. doi: 10.2337/dc08-s240. Review.

PMID:
18227478
10.

Recruitment to a clinical trial improves glycemic control in patients with diabetes.

Gale EA, Beattie SD, Hu J, Koivisto V, Tan MH.

Diabetes Care. 2007 Dec;30(12):2989-92. Epub 2007 Sep 5.

PMID:
17804681
11.

Hyperglycemia and its effect after acute myocardial infarction on cardiovascular outcomes in patients with Type 2 diabetes mellitus (HEART2D) Study design.

Milicevic Z, Raz I, Strojek K, Skrha J, Tan MH, Wyatt JW, Beattie SD, Robbins DC; HEART2D Study.

J Diabetes Complications. 2005 Mar-Apr;19(2):80-7.

PMID:
15745837
12.

Therapy after single oral agent failure: adding a second oral agent or an insulin mixture?

Malone JK, Beattie SD, Campaigne BN, Johnson PA, Howard AS, Milicevic Z.

Diabetes Res Clin Pract. 2003 Dec;62(3):187-95.

PMID:
14625133

Supplemental Content

Loading ...
Support Center